EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today announced an update on plans for filing its Biologics License Application (BLA) for Puricase® (pegloticase) for treatment-failure gout based on the results of its pre-BLA meeting with the U.S. Food and Drug Administration (FDA) reviewing division (Office of Drug Evaluation II) on April 17, 2008.
